DMT may protect brain tissue after stroke by reducing inflammation, preserving the blood-brain barrier, and improving recovery in preclinical models

DMT is being investigated as a potential neuroprotective treatment after stroke because it may reduce inflammation, limit brain swelling, and help preserve the blood-brain barrier during the acute injury phase. Preclinical findings suggest these effects could improve tissue survival and support better functional recovery even without relying on psychedelic subjective effects. Stroke causes a rapid cascade of oxygen deprivation, immune activation, and secondary cell damage, so compounds that interrupt those processes are of strong clinical interest. DMT has been linked to sigma-1 receptor activity and other signaling pathways associated with cellular stress responses, which may help explain why researchers are testing it in models of ischemic injury. The broader significance lies in psychedelic-adjacent drug development that separates therapeutic biology from hallucinogenic use. If these mechanisms translate to humans, DMT-derived or DMT-informed treatments could open a new path for emergency neurology and post-stroke care.